Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3633-3641

  Vosters, Jelle L ^a,b   Landek Salgado, Melissa A ^c   Yin, Hongen ^a   Swaim, William D ^a   Kimura, Hiroaki ^c   Tak, Paul P ^b   Caturegli, Patrizio ^c,e   Chiorini, John A ^a,d  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; INTERLEUKIN 12; PILOCARPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; LACRIMAL GLAND; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND DISEASE; SALIVARY GLAND FUNCTION; SALIVATION; SJOEGREN SYNDROME; TRANSGENIC MOUSE; WILD TYPE; XEROSTOMIA;

ANIMALS; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; BODY WEIGHT; CELL ENLARGEMENT; CELL PROLIFERATION; CHOLINERGIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-12; LACRIMAL APPARATUS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, TRANSGENIC; PILOCARPINE; SALIVARY GLANDS; SEX FACTORS; SJOGREN'S SYNDROME;

EID: 73249151654     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24980     Document Type: Article

References (24)

1. Hu Y, Nakagawa Y, Purushotham KR, Humphreys-Beher MG. Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol 1992;263:E607-14.
2. Humphreys-Beher MG, Brinkley L, Purushotham KR, Wang PL, Nakagawa Y, Dusek D, et al. Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin Immunol Immunopathol 1993;68:350-6.
3. Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, et al. NOD mouse model for Sjögren's syndrome: lack of longitudinal stability. Oral Dis 2006;12:566-72.
4. Yamano S, Atkinson JC, Baum BJ, Fox PC. Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol 1999;92:265-75.
5. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren's syndrome. Ann Rheum Dis 2006;65: 195-200.
6. Vosters JL, Baum BJ, Tak PP, Illei GG, Chiorini JA. Developing a gene therapy for Sjögren's syndrome. Future Rheumatol 2006; 1:433-40.
7. Van Blokland SC, Versnel MA. Pathogenesis of Sjögren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol 2002;103:111-24.
8. Kimura H, Tzou SC, Rocchi R, Kimura M, Suzuki K, Parlow AF, et al. Interleukin (IL)-12-driven primary hypothyroidism: the contrasting roles of two Th1 cytokines (IL-12 and interferon-γ). Endocrinology 2005;146:3642-51.
9. McGrath-Morrow S, Laube B, Tzou SC, Cho C, Cleary J, Kimura H, et al. IL-12 overexpression in mice as a model for Sjögren lung disease. Am J Physiol Lung Cell Mol Physiol 2006;291:L837-46.
10. Mathieu A, Cauli A, Pala R, Satta L, Nurchis P, Loi GL, et al. Tracheo-bronchial mucociliary clearance in patients with primary and secondary Sjögren's syndrome. Scand J Rheumatol 1995;24: 300-4.
11. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006;116:3183-94.
12. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis 2000;59:709-12.
13. Jara LJ, Navarro C, Brito-Zeron Mdel P, Garcia-Carrasco M, Escarcega RO, Ramos-Casals M. Thyroid disease in Sjögren's syndrome. Clin Rheumatol 2007;26:1601-6.
14. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther 2003;14:1605-18.
15. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 2002;29:938-44.
16. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
17. Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cell Mol Life Sci 1999;55:1610-25.
18. Trembleau S, Germann T, Gately MK, Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995;16:383-6.
19. Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci U S A 1995;92:4823-7.
20. Kawedia JD, Nieman ML, Boivin GP, Melvin JE, Kikuchi K, Hand AR, et al. Interaction between transcellular and paracellular water transport pathways through Aquaporin 5 and the tight junction complex. Proc Natl Acad Sci U S A 2007;104:3621-6.
21. Hagiwara E, Okubo T, Aoki I, Ohno S, Tsuji T, Ihata A, et al. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Cytokine 2000;12: 1035-41.
22. Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med 1996; 183:1447-59.
23. Mathsson L, Ahlin E, Sjowall C, Skogh T, Ronnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. Clin Exp Immunol 2007;147:513-20.
24. Adamson TC III, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8.